To generate a bispecific CAR T cell that can control both CD19+ B-cell lymphoma and CD19− loss variants with equal efficiency, Zah et al. determined the structural parameters for dual-antigen recognition and created CD19-OR-CD20 CAR, an “OR-gate CAR”, to trigger robust T cell function by either antigen expression [56]. Here, CD19 is linked to B-cell non-Hodgkin lymphoma.